Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: recommendations of an expert panel

Claudio Babiloni, Xianghong Arakaki, Hamed Azami, Laura Bonanni, Karim Bennys, Katarzyna Blinowska, Ana Bujan, Maria C. Carrillo, Andrzej Cichocki, Jaisalmer de Frutos-Lucas, Claudio Del Percio, Bruno Dubois, Rebecca Edelmayer, Gary Egan, Stephane Epelbaum, Javier Escudero, Alan Evans, Francesca Farina, Keith Fargo, Alberto FernándezRaffaele Ferri, Giovanni Frisoni, Harald Hampel, Michael G. Harrington, Vesna Jelic, Jaeseung Jeong, Yang Jiang, Maciej Kaminski, Voyko Kavcic, Kerry Kilborn, Sanjeev Kumar, Alice Lam, Lew Lim, Roberta Lizio, David Lopez, Susanna Lopez, Brendan Lucey, Fernando Maestú, William J. McGeown, Ian McKeith, Davide Vito Moretti, Flavio Nobili, Giuseppe Noce, John Olichney, Marco Onofrj, Ricardo Osorio, Mario Parra-Rodriguez, Tarek Rajji, Petra Ritter, Andrea Soricelli, Fabrizio Stocchi, Ioannis Tarnanas, John Paul Taylor, Stefan Teipel, Federico Tucci, Mitchell Valdes-Sosa, Pedro Valdes-Sosa, Marco Weiergräber, Gorsev Yener, Bahar Guntekin

Research output: Contribution to journalReview ArticleResearchpeer-review

36 Citations (Scopus)

Abstract

The Electrophysiology Professional Interest Area (EPIA) and Global Brain Consortium endorsed recommendations on candidate electroencephalography (EEG) measures for Alzheimer's disease (AD) clinical trials. The Panel reviewed the field literature. As most consistent findings, AD patients with mild cognitive impairment and dementia showed abnormalities in peak frequency, power, and “interrelatedness” at posterior alpha (8-12 Hz) and widespread delta (< 4 Hz) and theta (4-8 Hz) rhythms in relation to disease progression and interventions. The following consensus statements were subscribed: (1) Standardization of instructions to patients, resting state EEG (rsEEG) recording methods, and selection of artifact-free rsEEG periods are needed; (2) power density and “interrelatedness” rsEEG measures (e.g., directed transfer function, phase lag index, linear lagged connectivity, etc.) at delta, theta, and alpha frequency bands may be use for stratification of AD patients and monitoring of disease progression and intervention; and (3) international multisectoral initiatives are mandatory for regulatory purposes.

Original languageEnglish
Pages (from-to)1528-1553
Number of pages20
JournalAlzheimer's & Dementia
Volume17
Issue number9
DOIs
Publication statusPublished - Sep 2021

Keywords

  • Alzheimer's disease
  • biomarkers
  • clinical trials
  • dementia
  • electroencephalography (EEG)
  • eyes-closed resting state condition
  • The Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART)

Cite this